{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76"},{"groupId":"OG001","value":"0.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The overall adverse event rates for grade 3 or higher hematologic and non-hematologic adverse events at least possibly related to treatment will be compared between the two treatment groups using the Chi-square test (or Fisher's exact test if the data in the contingency table is sparse).","groups":[{"description":"Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.","id":"OG000","title":"Group I (Nivolumab)"},{"description":"Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Group II (Varlilumab, Nivolumab)"}],"paramType":"NUMBER","populationDescription":"All eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"25 months","title":"Proportion of Patients With Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"proportion of patients"}